Clinical trial

A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia

NCT01655680

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2012-05-01

PhasePHASE2

Study timeline

Study start (unknown)2012-05-01Date precision: month

Registry last updated2021-07-07

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Schizophreniaunresolved

Interventions

ABT-126DRUG

PlaceboDRUG

Sponsors & collaborators

AbbVie (prior sponsor, Abbott)lead sponsor

Mapped research locations

Saint PetersburgRussia7 MoscowRussia3 HoustonTexas, United States2 LondonUnited Kingdom2 San DiegoCalifornia, United States2 SaratovRussia2 ChicagoIllinois, United States1 PhiladelphiaPennsylvania, United States1 DallasTexas, United States1 AtlantaGeorgia, United States1 RochesterNew York, United States1 New HavenConnecticut, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01655680 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.